Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America, North America, and Europe. More Details
+ 1 more risk
Mediocre balance sheet with limited growth.
Share Price & News
How has Khiron Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KHRN is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: KHRN's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: KHRN underperformed the Canadian Pharmaceuticals industry which returned 36.7% over the past year.
Return vs Market: KHRN underperformed the Canadian Market which returned 29% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Khiron Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWe Think Shareholders Are Less Likely To Approve A Large Pay Rise For Khiron Life Sciences Corp.'s (CVE:KHRN) CEO For Now
2 months ago | Simply Wall StWe're Keeping An Eye On Khiron Life Sciences' (CVE:KHRN) Cash Burn Rate
Is Khiron Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KHRN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KHRN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KHRN is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: KHRN is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KHRN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KHRN is good value based on its PB Ratio (0.8x) compared to the CA Pharmaceuticals industry average (2.8x).
How is Khiron Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KHRN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KHRN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KHRN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KHRN's revenue (78.2% per year) is forecast to grow faster than the Canadian market (5.2% per year).
High Growth Revenue: KHRN's revenue (78.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KHRN is forecast to be unprofitable in 3 years.
How has Khiron Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KHRN is currently unprofitable.
Growing Profit Margin: KHRN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KHRN is unprofitable, and losses have increased over the past 5 years at a rate of 30.3% per year.
Accelerating Growth: Unable to compare KHRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KHRN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).
Return on Equity
High ROE: KHRN has a negative Return on Equity (-36.87%), as it is currently unprofitable.
How is Khiron Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: KHRN's short term assets (CA$28.3M) exceed its short term liabilities (CA$5.7M).
Long Term Liabilities: KHRN's short term assets (CA$28.3M) exceed its long term liabilities (CA$2.2M).
Debt to Equity History and Analysis
Debt Level: KHRN's debt to equity ratio (0.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if KHRN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KHRN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: KHRN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.4% each year
What is Khiron Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KHRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KHRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KHRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KHRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KHRN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alvaro Torres (42 yo)
Mr. Alvaro Francisco Torres is a Co-Founder of Khiron Life Sciences Corp. and has been its Chief Executive Officer since February 2017. He is a Director of Khiron Life Sciences Corp. since May 15, 2018 and...
CEO Compensation Analysis
Compensation vs Market: Alvaro's total compensation ($USD277.14K) is above average for companies of similar size in the Canadian market ($USD165.99K).
Compensation vs Earnings: Alvaro's compensation has been consistent with company performance over the past year.
Experienced Management: KHRN's management team is considered experienced (2.5 years average tenure).
Experienced Board: KHRN's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: KHRN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.4%.
Khiron Life Sciences Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Khiron Life Sciences Corp.
- Ticker: KHRN
- Exchange: TSXV
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$54.631m
- Shares outstanding: 179.12m
- Website: https://www.khiron.ca
- Khiron Life Sciences Corp.
- 2300-550 Burrard Street
- British Columbia
- V6C 2B5
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America, North America, and Europe. It operates through three segments: Medical Cannabis Products, Health Services...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/01 22:07|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.